1.A trend analysis on disease spectrum and cost constitution in inpatients aged over 65-year-old in Sichuan Provincial People's Hospital from 2010 to 2014
Guo CHEN ; Huaicong LONG ; Xiaohui LI ; Wei LI ; Yutian ZHOU ; Jiangyu YANG ; Biao CHENG
Chinese Journal of Geriatrics 2017;36(3):316-320
Objective To retrospectively investigate the disease spectrum of inpatients aged over 65 year and cost constitution in Sichuan Provincial People's Hospital from 2010 to 2014,so as to provide baseline data for further study.Methods The inpatients'disease spectrum and costs were collected from hospital information system.The diseases were classified according to the International Classification of Diseases(ICD-10).The data were analyzed using SPSS 18.0 software.Results The total number of old inpatients was 111,935,and male (55.2 %) was more than female (44.8 %).The average age was (74.5 ±6.8)years.The top four systematic diseases of primary diagnosis were circulatory system disease (21.0 %),respiratory system disease (13.7 %),digestive system disease (12.7%)and neoplasms (12.1%).The total number of male inpatients was more than the female inpatients.The average cost per capita was increased from (¥)18,778.1 yuan to (¥)23,391.9 yuan since 2010.The proportion of all costs accounted for by drugs in elderly inpatients was decreased from 45.5% to 38.9% since 2010.Nosocomial infection was decreased from 3.19% to 0.16% since 2010.Conclusions The number of elderly inpatients are more in male than in female in Sichuan Provincial People's Hospital from 2010 to 2014.The most common systematic disease is circulatory system diseases,and followed by respiratory system diseases,digestive system diseases and neoplasms.The proportion of all expenditures accounted for by drugs was declined in five years,while the average cost per capita is increased.
2.Mitochondrial Dysfunction and Huntington's Disease
Journal of Sun Yat-sen University(Medical Sciences) 2024;45(6):941-952
Huntington's disease (HD) is an autosomal dominant neurodegenerative disease caused by abnormal amplification of the CAG repeat of the huntingtin (HTT) gene. Its main clinical manifestations are movement disorders,cognitive decline,and psychiatric symptoms. The occurrence and development of HD is related to a variety of factors,and with the deepening of basic research,the relationship between mitochondrial dysfunction,including decreased energy production,abnormal mitochondrial dynamics,and calcium homeostasis. Huntington's disease has attracted more and more attention from researchers. In this review,we discuss the links that exist between the many forms of mitochondrial dysfunction and HD,with the aim of highlighting the important role of mitochondrial dysfunction in the development and progression of HD disease.
3.Progress in immunotherapy for hepatocellular carcinoma.
Zongyi SHEN ; Maochen LI ; Suhang BAI ; Qingkun YANG ; Fuhan ZHANG ; Mao TANG ; Jiangyu GUO ; Zhao YANG
Chinese Journal of Biotechnology 2019;35(12):2326-2338
Hepatocellular carcinoma (HCC) is one of the malignant tumors with the highest morbidity and mortality in the world. The morbidity and mortality of HCC are increasing every year. Liver cancer is a serious threat to public health in China and the death rate of patients with liver cancer in China is the highest in the world. Beyond surgery, chemotherapy and radiotherapy, immunotherapy is an emerging treatment for cancer, which could control and kill tumor cells by relieving the inhibitory status of immune cells in the tumor microenvironment and activating the immune function of the body. Immune checkpoint inhibitors, adoptive immunotherapy and tumor vaccine are the major treatments of immunotherapy. Compared with traditional therapy methods, immunotherapy could enhance immune function, delay tumor progression, prolong the survival time of patients, and becomes a hotspot in the basic and clinical cancer research. This article reviews the research progress of immunotherapy for liver cancer.
Cancer Vaccines
;
Carcinoma, Hepatocellular
;
therapy
;
China
;
Humans
;
Immunotherapy
;
Liver Neoplasms
;
therapy
;
Tumor Microenvironment